Detection of novel disease biomarkers, such as C-type lectin-like molecule-1 (CLL-1) and galectin-9 or the use of nanosensors for circulating DNA, microRNAs and leukemia-specific proteins might also significantly improve sensitivity of MFC-assays [16–19]. This evidence concerns the gene CLEC12A and leukemia.